isoquinoline-3-carbonyl azide | 1119545-65-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: isoquinoline-3-carbonyl azide
• 英文别名: 3-Isoquinolinecarbonyl azide
• CAS: 1119545-65-1
• 化学式: C₁₀H₆N₄O
• 分子量: 198.184
• InChiKey: BKHDVLNPBLSCKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  44.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  isoquinoline-3-carbonyl azide 以 甲苯 为溶剂， 反应 1.0h， 生成 3-isocyanatoisoquinoline
  参考文献：
  名称：

  Novel Tetrahydropyrido[1,2-a]isoindolone Derivatives (Valmerins): Potent Cyclin-Dependent Kinase/Glycogen Synthase Kinase 3 Inhibitors with Antiproliferative Activities and Antitumor Effects in Human Tumor Xenografts

  摘要：

  The development of CDK and GSK3 inhibitors has been regarded as a potential therapeutic approach, and a substantial number-of-diverse structures have been reported to inhibit CDKs and GSK-3 beta. in recent years. Only a few molecules have gone through or are currently undergoing clinical trials as CDK and GSK inhibitors. In this paper, we prepared valmerins, a new family containing the tetrahydropyrido[1,2-a]isoindone core. The fused heterocycle was prepared with a straightforward synthesis that was functionalized by a (het)arylurea. Twelve valmerins inhibited the CDK5 and GSK3 with an IC50 < 100 nM. A semiquantitative kinase scoring was realized, and a cellular screening was done. At the end of study, we investigated the in vivo potency of one valmerin. Mice exhibited good tolerance to our lead, which proved its efficacy and clearly blocked tumor growth. Valmerins appear also as good candidates: for further development as anticancer agents.

  DOI：

  10.1021/jm3008536
• 作为产物：
  描述：

  isoquinoline-3-carboxylic acid chloride 在 sodium azide 作用下， 以 水 为溶剂， 反应 1.0h， 生成 isoquinoline-3-carbonyl azide
  参考文献：
  名称：

  Novel Tetrahydropyrido[1,2-a]isoindolone Derivatives (Valmerins): Potent Cyclin-Dependent Kinase/Glycogen Synthase Kinase 3 Inhibitors with Antiproliferative Activities and Antitumor Effects in Human Tumor Xenografts

  摘要：

  The development of CDK and GSK3 inhibitors has been regarded as a potential therapeutic approach, and a substantial number-of-diverse structures have been reported to inhibit CDKs and GSK-3 beta. in recent years. Only a few molecules have gone through or are currently undergoing clinical trials as CDK and GSK inhibitors. In this paper, we prepared valmerins, a new family containing the tetrahydropyrido[1,2-a]isoindone core. The fused heterocycle was prepared with a straightforward synthesis that was functionalized by a (het)arylurea. Twelve valmerins inhibited the CDK5 and GSK3 with an IC50 < 100 nM. A semiquantitative kinase scoring was realized, and a cellular screening was done. At the end of study, we investigated the in vivo potency of one valmerin. Mice exhibited good tolerance to our lead, which proved its efficacy and clearly blocked tumor growth. Valmerins appear also as good candidates: for further development as anticancer agents.

  DOI：

  10.1021/jm3008536

文献信息

• [EN] INHIBITION OF OLIG2 ACTIVITY<br/>[FR] INHIBITION DE L'ACTIVITÉ D'OLIG2
  申请人：CURTANA PHARMACEUTICALS INC

  公开号：WO2018039621A1

  公开（公告）日：2018-03-01

  Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物抑制Olig2的活性。本文还描述了使用这种Olig2抑制剂的方法，单独或与其他化合物结合，用于治疗癌症和其他疾病。特别是Olig2抑制剂可用于治疗胶质母细胞瘤。
• Certain chemical entities, compositions, and methods
  申请人：Qian Xiangping

  公开号：US20090275537A1

  公开（公告）日：2009-11-05

  Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.

  本文描述了调节平滑肌肌球蛋白和/或非肌肉肌球蛋白的化学实体、制药组合物以及治疗与平滑肌肌球蛋白和/或非肌肉肌球蛋白相关的疾病和病状的方法。
• CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
  申请人：QIAN Xiangping

  公开号：US20120135964A1

  公开（公告）日：2012-05-31

  Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.

  本文描述了调节平滑肌肌球蛋白和/或非肌肉肌球蛋白的化学实体、制药组合物和治疗与平滑肌肌球蛋白和/或非肌肉肌球蛋白相关的疾病和病状的方法。
• Inhibition of OLIG2 activity
  申请人：CURTANA PHARMACEUTICALS, INC.

  公开号：US11242323B2

  公开（公告）日：2022-02-08

  Described herein are urea compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.

  本文描述了抑制 Olig2 活性的脲化合物和含有此类化合物的药物组合物。本文还描述了使用此类 Olig2 抑制剂单独或与其他化合物联合治疗癌症和其他疾病的方法。特别是 Olig2 抑制剂可用于治疗胶质母细胞瘤。
• INHIBITION OF OLIG2 ACTIVITY
  申请人：Curtana Pharmaceuticals, Inc.

  公开号：EP3504195A1

  公开（公告）日：2019-07-03